Accuracy of 68Ga-Pentixafor PET/CT for Subtypting Diagnosis in Patients With Primary Aldosteronism Concurrent With Autonomous Cortisol Secretion

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorQifu Li

About this trial

To evaluate the accuracy of 68Ga-Pentixafor PET-CT in the classification diagnosis of primary aldosteronism concurrent with autonomous cortisol secretion patient, using AVS and/or postoperative remission as the reference standard for classification diagnosis.

Eligibility criteria

Qualifiers

Getting the written informed consent

The clear diagnosis of primary aldosteronism;

Combined with autonomous cortisol secretion, cortisol after 1mg dexamethasone suppression test (DST) ≥50 nmol/l;

Patients who are willing to undergo surgery;

Disqualifiers

PA patients who meet the by-passing AVS criteria [i.e., younger than 35 years old, spontaneous hypokalemia, adrenal CT indicated unilateral low-density adenoma (≥1cm), plasma aldosterone >300pg/ml];

Suspicion of familial hyperaldosteronism or Liddle syndrome. [i.e., age <20 years, hypertension and hypokalemia, or with family history];

Suspicion of pheochromocytoma or adrenal carcinoma;

Patients with actively malignant tumor;

Trial design

Treatments tested in this trial

  • 68Ga-Pentixafor PET/CT

Treatment groups

No treatment groups listed

Sponsors and collaborators

Qifu Li

Lead sponsor

Chongqing Medical University

Sponsor institution

The First Affiliated Hospital of Zhengzhou University

Collaborator

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Collaborator

The Third Xiangya Hospital of Central South University

Collaborator

The Affiliated Hospital Of Southwest Medical University

Collaborator